Santaris Raises $12M in Private Investment Round | GenomeWeb

Santaris Pharma this week announced that it has raised $12 million through the sale of convertible bonds to existing private investors and members of the company's management.

Santaris said that proceeds from the financing would primarily be used to fund the continued development of its microRNA-targeting hepatitis C drug miravirsen, which is under phase II development, as well as its pipeline of other locked nucleic acid-based therapeutic candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.